Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy. Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell™ technology. WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat ...

The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level. Endpoints measuring the reduction of viral load and the presence of cellular and humoral antiCOVID-19 responses after treatment were met. Fifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients. Treatment arm patients were infect ...

WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company's ambition to address the Long COVID crisis as its leadership met with Congress on Capitol Hill last week. "It was an honor to meet with congressional teams in Washington, D.C., to address the urgent challenge of L ...

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Tevogen Bio Inc (Nasdaq: TVGN), please note that paragraph two has been updated. The corrected release follows: Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter e ...

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating acti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-41002 | --- | --- | |------------------------------------------------------------------------------------ ...

WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding Inc. ("Tevogen" or "Tevogen Bio") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio's Innovation and Public Health Advisory Board, on being named as the dean of the USF Health College of Public Health, effective January 1, 2025. In addition ...

WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 (File No. 333-280414) on June 21, 2024, which was declared effective by the Securities and Exchange Commission on August 2, 2024, to register the issuance of earnout shares and shares un ...

We are pleased to share our progress and next steps that underscore our commitment to advancing science to benefit patients and physicians while supporting our stockholder's investment. We are also happy to share that since its inception, Tevogen.AI has made strides in its mission to enhance drug discovery through predictive modeling. About Tevogen Bio Forward-Looking Statements You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertak ...

We are also happy to share that since its inception, Tevogen.AI has made strides in its mission to enhance drug discovery through predictive modeling. We continue to emphasize our achievements, highlighting that our cost-effective business model has been instrumental in driving this level of progress. Independent equity research has initiated coverage echoing this sentiment. In light of recent stock performance, we understand the concerns some of you may have regarding Tevogen Bio's current share price. We ...